Ravi Madan

32PUBLICATIONS
96CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyLinguistic anthropology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Sep 14, 2026
Intermittent enzalutamide in recurrent prostate cancer: testosterone kinetics and related toxicity.

|Aug 21, 2026
APUC-6 Genes as a Potential Prognostic and Predictive Biomarker in the CHAARTED Prostate Cancer Trial.

|Jul 24, 2026
Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.

|Mar 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Chennan Li, Ravi A Madan, Min-Jung Lee

|Feb 11, 2026
Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.

Rana R McKay, Benjamin L Maughan, Alicia K Morgans

|Oct 23, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.

David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching

Pageof 6

Frequent Collaborators

13 joint publications

Fatima Karzai

13 joint publications

James L Gulley

9 joint publications

Marijo Bilusic

9 joint publications

Jeffrey Schlom